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Precis for use in the Table of Contents (2 sentences) 
In a cohort of over 700 patients with prospective health related quality of life information, 
prostate stereotactic body radiation therapy has minimal long-term impact on clinically 
detectable declines in global quality of life. Baseline poor bowel function and clinical depression 
are associated with an increased rate of multi-domain decline. 
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Abstract 
Background:  Stereotactic body radiation therapy (SBRT) for localized prostate cancer involves 
high dose per fraction radiation treatments. Utilization is increasing, but concerns remain about 
treatment-related toxicity. We assess the incidence and predictors of a global decline in health-
related quality of life (HRQOL) after prostate SBRT. 
 
Methods: From 2008-2014, 713 consecutive men with localized prostate cancer were treated 
with SBRT per a prospective institutional protocol. Expanded Prostate Cancer Index Composite 
(EPIC-26) HRQOL data were collected at baseline and longitudinally for 5-years. EPIC-26 is 
comprised of 5 domains. The primary endpoint was defined as a decline exceeding the clinically 
detectable threshold in ≥4 EPIC-26 domains, termed “multi-domain decline”.   
 
Results: Median age was 69 years old, 46% were unfavorable intermediate- or high-risk, and 
20% received androgen deprivation therapy.  During 1-3 and 6-60 months post-SBRT, 8-15% 
and 10-11% of patients had a multi-domain decline, respectively. On multivariable analysis, 
lower baseline bowel HRQOL (odds ratio 1.8 [95%CI 1.2-2.7], p<0.01) and baseline depression 
(odds ratio 5.7 [95%CI 1.3-24.3], p=0.02) independently predicted for multi-domain decline. 
Only 3-4% of patients had long-term multi-domain decline exceeding twice the clinical 
threshold, of which 30% appeared to be related to prostate cancer treatment or progression of 
disease. 
 
Conclusions: Prostate SBRT has minimal long-term impact on multi-domain decline, and of 
those with more significant multi-domain decline, the majority appear to be unrelated to 
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treatment. This emphasizes the importance of focusing not only on the side effects of prostate 
cancer treatment, but also on other comorbid illnesses that contribute to overall HRQOL. 
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Introduction: 
Prostate stereotactic body radiation therapy (SBRT) is an emerging treatment for 
localized prostate cancer. Single institution 
1-3
 and multi-institutional 
4
 experiences have reported 
promising results with intermediate term follow-up, and phase III trials are ongoing.
5,6
 SBRT is 
convenient as it is delivered over just 5 treatments instead of the more standard 44 treatments, 
appears cost effective 
7
, and utilization is on the rise in the United States.
8
  
Despite encouraging tumor control results, concerns remain about the long-term toxicity 
associated with ultra-hypofractionated treatment (i.e. SBRT) to the prostate.
9,10
 Others have 
reported more promising results. Widely regarded as the ‘gold standard’ for assessing HRQOL in 
prostate cancer, the Expanded Prostate Cancer Index Composite (EPIC) inventory captures 5 
different domains of quality of life: urinary incontinence, urinary irritative, bowel, sexual, and 
vitality.
11
 Pooled multi-institutional results to date have demonstrated minimal impact of prostate 
SBRT on select and solitary HRQOL, including the urinary, bowel, and sexual domains.
12
 
However, no data exists on patients who experience declines in multiple concurrent domains, a 
side effect profile that may be more burdensome for patients and more difficult to manage for 
physicians.
13
 Furthermore, the vast majority of published studies to date have focused on patients 
with low risk disease, and less is known about HRQOL in men with unfavorable intermediate 
and high risk disease after prostate SBRT, especially with the addition of androgen deprivation 
therapy. As such, more work is needed to better understand the implications of SBRT on 
HRQOL.  
We hypothesize that an underappreciated group of men exists with clinically detectable, 
multi-domain HRQOL decline following treatment. Using a novel framework, we analyze a 
large, diverse cohort of men with prostate cancer, all treated with SBRT with prospectively 
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collected HRQOL. We aim to assess the incidence of and determine patient- and treatment-
factors associated with multi-domain decline.  
 
Methods and Materials 
Patients 
Between January 2008 and September 2014, 830 consecutive men with localized biopsy-
proven prostate cancer were treated with SBRT per two institutional protocols 
(ClinicalTrials.gov NCT01766492, NCT01618851) or on a prospective registry per protocol. 
Node negative, non-metastatic patients were eligible (T1c-T3b disease, Gleason score 6-10, and 
PSA <50 ng/mL). High risk patients were staged with a bone scan and CT of the abdomen and 
pelvis. Baseline prostate-specific antigen (PSA) levels were obtained prior to initiation of 
therapy.  
Per protocol, Health Related Quality of Life (HRQOL) data were prospectively collected 
utilizing the EPIC-26 
11
. HRQOL data collection occurred at baseline. Post-SBRT data collection 
occurred at 1 month, 3 months for 2 years, and every 6 months thereafter. Of the 830 patients, 
117 were administered androgen deprivation prior to baseline HRQOL collection confounding 
the baseline results and were excluded leaving 713 eligible patients available for analysis that 
forms the study cohort.  
 
Treatment 
Volume delineation of the prostate and seminal vesicles was defined using a registration 
of the pretreatment MRI with the pretreatment CT simulation. Treatment planning details of 
prostate SBRT alone as well as external beam radiotherapy plus SBRT boost (IMRT+SBRT 
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boost) have been previously described.
14,15
 Dose prescription was 35-36.25 Gy in 5 fractions for 
SBRT. Certain higher risk patients were treated with IMRT+SBRT boost; dose prescription 
included 45-50.4 Gy in 1.8 Gy fractions of IMRT plus 19.5 Gy in 3 fractions of SBRT. 
Treatment was delivered using Cyberknife (Accuray, Sunnyvale CA) and gold fiducials aided 
with imaged-guided delivery. Neoadjuvant androgen deprivation therapy (ADT) consisted of an 
LHRH agonist. ADT was prescribed primarily to unfavorable intermediate and high risk patients 
for 3-6 months duration.  
 
Endpoints 
EPIC-26 is divided into 5 major symptom domains: urinary incontinence, urinary 
irritative, bowel, sexual, and vitality.
11
 Individual question results within each domain are 
transformed and averaged to generate a summary score ranging from 0 to 100; higher scores 
represent better HRQOL.  
“Minimally Important Difference” (MID) thresholds establish levels beyond which 
changes in quality of life measures are considered clinically detectable.
16
 Recent work by 
Skolarus et al utilized distribution-based and anchor-based techniques to establish specific MID 
thresholds for each of the EPIC-26 domains.
17
 We utilized the midpoint of the Skolarus et al 
MID estimates for each domain: urinary incontinence (7.5), urinary irritative (6.0), bowel (5.0), 
sexual (11.0), and vitality (5.0); each defined as 1x MID change. 
Our primary endpoint was defined as patients with declines equal to or exceeding the 
MID threshold in 4 or 5 domains concurrently (termed 1x multi-domain decline). Those with 
greater global declines, defined by declines equal to or exceeding twice the MID threshold in any 
4 or 5 domains concurrently, were also documented (termed 2x multi-domain decline).  
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Covariables 
Pretreatment covariables included age (continuous), body mass index (BMI, kg/m2, 
continuous), prostate volume (cubic centimeters (cc), continuous), baseline diabetes (binary, yes 
or no), current smoker (binary, yes or no), anticoagulation (binary, yes or no), Charlson 
Comorbidity 
18
 (binary, greater than or less than 2), baseline depression (binary, yes or no), and 
partner status (binary, yes or no). Pretreatment HRQOL variables included baseline incontinence, 
irritative, and bowel domains (continuous). Treatment-related covariables included ADT use 
(binary, use or non-use, as all patients were treated with short-term ADT).  
 
Statistical Analysis 
Descriptive statistics were used to describe the incidence of 1x and 2x multi-domain 
decline over time, reporting the percentage and 95% confidence interval (CI). Univariable and 
multivariable logistical regression was performed to generate models of predictors of 1x multi-
domain decline at 36-months post-SBRT. Complete HRQOL data were available in 299 men at 
36 months (88% response rate), and of the 299 men, baseline comorbid characteristics were 
available for 72% (n = 215) (Supplementary Table 1). Odds ratios (OR), adjusted OR (AOR), 
and 95% CI are reported. Two-sided P values of 0.05 were considered statistically significant. 
Statistical analyses were performed using IBM SPSS version 24.0 (SPSS Inc., Chicago, IL 
USA).  
 
Results 
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Table 1 demonstrates the characteristics of the patient cohort. Median age was 69 years 
old (IQR 64-73). Most patients treated were intermediate risk (57%, n=407) or high risk (19%, n 
= 132). Twenty percent (n = 145) of patients received short-term ADT. Response rates with 
complete HRQOL information were 88% or greater at all time points, and remained consistent 
over time (Table 2). Prior to treatment, most men had excellent urinary incontinence, bowel, and 
vitality domains with median function of 100 (Table 1). The urinary irritative domain was 
slightly more impaired at baseline with a median of 88 (interquartile range (IQR) 75-100)). 
Sexual dysfunction was common and highly variable at baseline with a median of 61 (IQR 26-
83).  
 
Individual domain HRQOL decline 
The incidence of urinary irritative, bowel, and vitality domain 1x and 2x MID decline 
generally improved after an initial decrement post-treatment (Figure 1A and 1B).  For example, 
at 1 month 54% (95% CI 50-58%) of patients had a 1x MID decline in the urinary irritative 
domain, which improved to 28% (95% CI 20-35%) of patients at 5-years post-SBRT, p<0.001. 
In contrast, the sexual domain 1x and 2x MID decline worsened over time. At 1-month post 
treatment 39% (95% CI 35-43%) of patients reported a 1x MID sexual domain decline, which 
increased to 56% reporting a decline (95% CI 47-64%) at 5-years post-SBRT, p<0.001. The 
urinary incontinence domain remained stable over time.  
 
Rates of multi-domain decline 
In the acute setting 1-3 months post SBRT, approximately 10-15% of patients exceed the 
threshold for clinical detectable decline in 4 or more domains and meet our definition of 1x 
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multi-domain decline (Figure 2A). Between 3-6 months, the incidence of 1x and 2x multi-
domain decline is lower as the acute bowel and urinary irritative side effects subside from SBRT, 
and before sexual domain declines peak. Long-term, 2-5 years post-treatment, ~10% of patients 
continue to report 1x multi-domain declines. As for those patients with more significant declines, 
~5% of men experience 2x multi-domain decline in the acute setting, which decreased to 3-4% 
2-5 years post-treatment (Figure 2B). Of the 29 patients reporting 1x or 2x multi-domain decline 
at 36 months, 79% (n = 23) reported “moderate” or “big” problem in at least one domain. 
 
Predictors of Multi-domain decline 
On univariable analysis, lower baseline bowel HRQOL (OR 1.38 per 10 point decrease 
[95%CI 1.02-1.87], p=0.04) and a baseline diagnosis of depression (OR 4.13 [95% CI 1.00-
17.01], p=0.05) were significantly associated with multi-domain decline (Table 3). Age, BMI, 
prostate volume, baseline diabetes, smoking status, anticoagulation use, Charlson comorbidity, 
partner status, baseline urinary incontinence or irritative HRQOL and use of ADT were not 
significantly associated with multi-domain decline. 
On multivariable analysis, those with worse baseline bowel HRQOL had an increased 
likelihood of having 1x multi-domain decline (AOR of 1.82 per 10 point decrease [95% CI 1.21-
2.73], p<0.01). Of the patients with 1x multi-domain decline, seven had baseline bowel function 
in the lowest quartile. Five of the seven (71%) had identifiable bowel disease (two with prior 
history of colorectal cancer, one hemophilia and chronic small bowel obstructions, one with 
severe hemorrhoids and incontinence, and one with chronic diverticulitis). One of the two 
without bowel disease had a clinical diagnosis of depression, but no overt diagnosis of irritable 
bowel syndrome. In addition to poor bowel function prior to treatment, a baseline clinical 
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diagnosis of depression was significantly associated with a >5-fold increase in 1x multi-domain 
decline (AOR 5.65 [95%CI 1.31-24.26], p=0.02).  
Of the 3.0% of patients (n = 13) reporting a more significant, 2x multi-domain decline at 
36 months, 53% of patients (n = 7), experienced concomitant declines in their health status 
unrelated to prostate cancer or treatment. These declines included a new pituitary tumor, a new 
diagnosis of pulmonary fibrosis, a recurrent bladder tumor, among others (Table 4). Thirty 
percent (n = 4), experienced either disease related decline (metastasis and ADT) or persistent 
radiation side effects such as radiation cystitis or urinary incontinence. Others reported a global 
decline without a clear etiology that may or may not be treatment related (n = 2).  
 
Discussion 
The modern definition of prostate cancer treatment success involves cure with preserved 
quality of life.
19
 As noted by Sanda et al, Resnick et al, and the recently reported Prostate Testing 
for Cancer and Treatment (ProtecT) randomized trial, patient reported outcomes differ amongst 
definitive treatment strategies.
20-22
 Those undergoing radical prostatectomy (RP) are more likely 
to report declines in urinary incontinence and sexual function whereas those receiving 
conventionally fractionated radiation (EBRT) are more likely to report rectal bleeding. Less is 
known about the side-effect profile of SBRT, particularly its impact on global decline. As we 
await randomized data from trials such as Prostate Advances in Comparative Evidence (PACE, 
NCT01584258)
5
 which will compare SBRT to RP and EBRT, our data provides insight as to the 
expected patient-reported outcomes post-SBRT and addresses concerns related to treatment with 
high doses per fraction.     
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Using a novel patient-level analysis, our findings support that prostate SBRT is generally 
well tolerated with low incidence of global decline following treatment. With up to 5 years of 
follow-up, 90% of patients do not meet the minimum threshold for detection of multi-domain 
decline using EPIC-26, a gold standard in patient reported HRQOL. In the subset of the 3-4% 
patients with more substantial multi-domain decline at 3 years, over 50% of patients experienced 
a decline in their general health status likely unrelated to prostate cancer or treatment. To our 
knowledge, this is the first comprehensive report of global HRQOL following SBRT and is 
particularly unique given the diverse patient population and detailed patient-level comorbidity 
detail.  
Our findings are consistent with others investigating the impact of SBRT on select and 
solitary domains of HRQOL. In 2013, King et al reported their multi-institutional pooled 
analysis of HRQOL following prostate SBRT. Tumor control outcomes were promising, and 
there were acceptable rates of sexual, urinary, and bowel domain HRQOL declines.
12,23
 Evans et 
al reported HRQOL was similar to brachytherapy and IMRT with respect to mean urinary (p > 
0.5) and sexual domains (p = 0.57), but was associated with better mean bowel function (6.7 
points, p <0.01).
24
 Unfortunately, most studies published to date often do not provide baseline 
comorbidity to understand the impact of these factors on HRQOL. Our study provides further 
support that SBRT is well tolerated with comparable rates of solitary domain decline to the 
published literature, and demonstrate there is also minimal multi-domain decline in our higher-
risk population, 20% of which received ADT. Furthermore, our baseline comorbidity detail 
provides additional key insight as to those most likely to report decline.  
Several studies have demonstrated preexisting anal disease (fissures, hemorrhoids) 
25
 and 
bowel disease (Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS)) 
26
 have been 
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associated with bowel toxicity following treatment with conventionally fractionated 
radiotherapy. While previous studies suggest that patient-reported bowel function is less affected 
by SBRT compared to conventional fractionation 
24
, our findings suggest that those with poor 
baseline function remain at higher risk of multi-domain decline (AOR 1.8 [95% CI 1.21-2.73] 
per 10 points). It is unknown whether these patients have inherently radiosensitive tissue and 
generalized radiation-induced dysfunction is thus more likely in these patients or that poor bowel 
function itself impacts other domains (i.e. urinary problems, avoiding sexually activity, and 
fatigue). Of the patients with multi-domain decline and bowel function in the lowest quartile, 
71% had identifiable preexisting bowel disease. These patients with poor baseline bowel 
function should be counseled as to the risks of treatment and aggressively managed in the acute 
and long-term setting. While not prospectively documented in our cohort, patients with IBS 
should also be of concern, given that most studies demonstrate the prevalence of concurrent 
psychiatric disorders in IBS to be 90% or higher.
27
 The most common psychiatric diagnosis 
associated with IBS is major depression, which is also an important comorbidity to be mindful of 
based on our results. 
Baseline depression was associated with a >5-fold increase in multi-domain decline at 36 
months. This finding is consistent with Mohamed et al, who reported that pretreatment 
depressive symptoms were associated with patient-reported HRQOL declines in urinary and 
sexual function in a group of 1,370 men treated with either radical prostatectomy, brachytherapy, 
or external beam radiation.
28
 As this increased side effect profile appears to be prevalent across 
multiple definitive modalities, pretreatment counseling and optimized psychiatric care should be 
prioritized.  Furthermore, >50% of patients who experienced a 2x multi-domain decline had an 
unrelated decline in their general health, highlighting the importance of comprehensive 
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survivorship care following treatment, and stresses the importance of treating the patient and not 
simply their prostate cancer.  
 Several limitations of our study are worthy of discussion. With conventionally 
fractionated radiotherapy, symptoms stabilize at 3 years 
29
,  however less is known about the late 
side effects of ultra-hypofractionated treatment. While over 100 patients had longer than 5 years 
of follow-up, the majority of our patients had 3 or less years of follow up and continued close 
monitoring of long-term side effects are warranted. It is possible that unaccounted for 
confounding variables, such as insurance status, may have affected our results.
30
 We are limited 
in making conclusions regarding dose-volume relationships as they were not available for 
analysis. Preliminary work suggest minimal dosimetric impact on MID declines across most 
domains.
31
 Finally, our models have not been independently validated. 
 
Conclusion 
In conclusion, prostate SBRT appears to have minimal long-term impact on clinically 
detectable, multi-domain declines up to 5 years post-treatment. Further follow-up and 
independent validation is warranted to confirm these promising findings.  Moreover, we eagerly 
await the long-term results of randomized control trials such as PACE (NCT01584258) which 
will compare both efficacy and HRQOL of radical prostatectomy, SBRT, and conventionally 
fractionated radiotherapy in low and intermediate-risk patients. In addition to solitary domain 
comparison, we recommend cross modality comparison of multi-domain decline and capturing 
of baseline comorbidities, including depression, to better understand the impact of treatment 
itself on HRQOL.  
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Figure 1: EPIC Solitary Domain Decline 
Panel (A) represents the incidence of patients with a solitary domain decline equal to or 
exceeding the threshold for clinical detection estimated by Skolarus et al 
17
 (Minimally 
Importance Difference (MID) 1x Decline). Panel (B) represents incidence of a decline equal to 
or exceeding twice the clinical threshold for detection (Minimally Importance Difference 2x 
Decline). Parenthesis represent 95% confidence intervals. 1-month post-treatment declines are 
compared to the decline at 60 months; * represents p-value < 0.01.  Abbreviations: EPIC, 
Expanded Prostate Cancer Index Composite.  
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Figure 2: EPIC Multi Domain Decline 
Panel (A) represents the incidence of patients with a multi-domain decline equal to or exceeding 
the  threshold for detection estimated by Skolarus et al 
17
 in 4 or more of the 5 EPIC domains 
(Multi-domain 1x Decline).  Panel (B) represents the incidence of patients with a decline equal to 
or exceeding twice the threshold for clinical detection in 4 or more of the 5 EPIC domains 
(Multi-domain 2x Decline).   Abbreviations: EPIC, Expanded Prostate Cancer Index Composite. 
Error bars represent 95% confidence intervals.  
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Table 1:  Patient Characteristics 
Abbreviations: PSA, prostate specific antigen; ADT, androgen deprivation therapy; BMI, body 
mass index; HRQOL, health related quality of life  
* Risk group adapted from National Comprehensive Cancer Network (NCCN) risk classification 
and the intermediate risk classification proposed by Zumsteg and Spratt.
32
 
** All ADT administered neoadjuvantly for 3-6 months.
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Table 2:  EPIC-26 Response Rates 
 
Abbreviations: EPIC, Expanded Prostate Cancer Index Composite.  
* Represent total men with follow-up at or beyond time point. 
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Table 3: Univariable and Multivariable Analysis of Predictors of Multi-Domain Decline at 
36 Months 
 
* Continuous variables; † Per 10 point decrease in HRQOL. 
Abbreviations: BMI, body mass index; HRQOL, health related quality of life; ADT, androgen 
deprivation therapy; OR, odds ratio; CI, confidence interval 
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Table 4: Detail of Patients with 2x Multi-domain Decline at 36 months 
Includes all patients with incidence of a decline equal to or exceeding twice the clinical threshold 
for detection estimated by Skolarus et al 
17
 in 4 or more of the 5 EPIC domains at 36 months (2x 
Multi-domain decline). Abbreviations: EPIC, Expanded Prostate Cancer Index Composite.   
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Table 1:  Patient Characteristics 
Patients   N= 713 % 
     
Age (years)    
Median (IQR)  69.0 (64-73) 
   44.00  
T-Stage     
T1c-T2a   575 81% 
T2b-c   132 19% 
T3   6 1% 
     
Gleason score    
<= 6   247 36% 
3+4   250 37% 
4+3   121 18% 
4+4   59 9% 
9-10   36 8% 
     
Pretreat PSA (ng/dl)    
≤10   519 73% 
>10 to ≤20  135 19% 
>20   59 8% 
     
Risk Group *    
Low   174 24% 
Favorable Intermediate 214 30% 
Unfavorable Intermediate 193 27% 
High   132 19% 
     
ADT **     
Yes   145 20% 
No   568 80% 
     
Prostate Volume (cc)    
Median (IQR)  37 (28-50) 
     
BMI (kg/m2)     
Median (IQR)  27 (25-31) 
     
Baseline HRQOL  Median IQR 
Urinary Incontinence  100 (86-100) 
Urinary Irritative  88 (75-100) 
Bowel   100 (92-100) 
Sexual   61 (26-83) 
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Table 2:  EPIC-26 Response Rates 
Follow-up Time period (months) 
1 3 6 12 24 36 60 
Number of Respondents 659 616 570 503 401 299 133 
Total * 697 665 624 559 449 339 141 
Response rate 95% 93% 91% 90% 89% 88% 94% 
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Table 3: Univariable and Multivariable Analysis of Predictors of Multi-Domain Decline at 
36 Months 
Univariable Analysis Multivariable Analysis 
36 months 36 months 
OR CI p OR CI p 
Age * 1.02 0.97 1.08 0.46 
BMI * 0.99 0.93 1.06 0.78 
Prostate Volume * 1.00 0.98 1.02 0.95 
         
Baseline Diabetes (yes vs no) 1.38 0.43 4.40 0.59     
Current smoker (yes vs no) 0.44 0.06 3.43 0.43     
Anticoagulation use (yes vs no) 0.94 0.37 2.40 0.89 
Charlson Cormorbidity > 2  1.43 0.56 3.68 0.46 
Baseline Depression (yes vs no) 4.13 1.00 17.01 0.05 5.65 1.31 24.26 0.02 
Partner status (yes vs no) 0.42 0.16 1.10 0.08     
         
Baseline Incontinence HRQOL † 1.17 0.94 1.44 0.15     
Baseline Irritative HRQOL † 0.87 0.68 1.13 0.30     
Baseline Bowel HRQOL † 1.38 1.02 1.87 0.04 1.82 1.21 2.73 <0.01 
         
ADT use (yes vs no) 0.70 0.20 2.44 0.58 
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Table 4: Detail of Patients with 2x Multi-domain Decline at 36 months 
Unrelated to treatment (7) 
Hypogonadism secondary to pituitary tumor (1) 
Major depressive episode (1) 
New diagnosis of pulmonary fibrosis (1) 
Recent nephrolithiasis diagnosis (1) 
Recurrent bladder cancer (1) 
Unemployed and alcohol abuse (1) 
Worsening of morbid obesity and metabolic syndrome (1) 
Disease or treatment related (4) 
Metastasis and initiation of androgen deprivation therapy (1) 
Radiation cystitis (1) 
Recent urinary tract infection and sepsis (1) 
Urinary incontinence (1) 
Unclear or unknown (2) 
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Figure 1: EPIC Solitary Domain Decline: Panel (A) represents the incidence of patients with a solitary 
domain decline equal to or exceeding the threshold for clinical detection estimated by Skolarus et al 17 
(Minimally Importance Difference (MID) 1x Decline). Panel (B) represents incidence of a decline equal to or 
exceeding twice the clinical threshold for detection (Minimally Importance Difference 2x Decline). 
Parenthesis represent 95% confidence intervals. 1-month post-treatment declines are compared to the 
decline at 60 months; * represents p-value < 0.01. Abbreviations: EPIC, Expanded Prostate Cancer Index 
Composite.  
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Figure 1: EPIC Solitary Domain Decline: Panel (A) represents the incidence of patients with a solitary 
domain decline equal to or exceeding the threshold for clinical detection estimated by Skolarus et al 17 
(Minimally Importance Difference (MID) 1x Decline). Panel (B) represents incidence of a decline equal to or 
exceeding twice the clinical threshold for detection (Minimally Importance Difference 2x Decline). 
Parenthesis represent 95% confidence intervals. 1-month post-treatment declines are compared to the 
decline at 60 months; * represents p-value < 0.01. Abbreviations: EPIC, Expanded Prostate Cancer Index 
Composite.  
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Figure 2: EPIC Multi Domain Decline: Panel (A) represents the incidence of patients with a multi-domain 
decline equal to or exceeding the threshold for detection estimated by Skolarus et al 17 in 4 or more of the 
5 EPIC domains (Multi-domain 1x Decline). Panel (B) represents the incidence of patients with a decline 
equal to or exceeding twice the threshold for clinical detection in 4 or more of the 5 EPIC domains (Multi-
domain 2x Decline). Abbreviations: EPIC, Expanded Prostate Cancer Index Composite. Error bars represent 
95% confidence intervals.  
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Figure 2: EPIC Multi Domain Decline: Panel (A) represents the incidence of patients with a multi-domain 
decline equal to or exceeding the threshold for detection estimated by Skolarus et al 17 in 4 or more of the 
5 EPIC domains (Multi-domain 1x Decline). Panel (B) represents the incidence of patients with a decline 
equal to or exceeding twice the threshold for clinical detection in 4 or more of the 5 EPIC domains (Multi-
domain 2x Decline). Abbreviations: EPIC, Expanded Prostate Cancer Index Composite. Error bars represent 
95% confidence intervals.  
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Supplemental Table 1: Baseline Comorbidities 
Age 
Mean  (IRQ) 69 (64-73) 
BMI 
Mean (IRQ) 29 (25-31) 
Prostate Volume 
Mean (IRQ) 41 (28-50) 
Baseline Diabetes * 
  Yes 34 16% 
  No 181 84% 
Current Smoker * 
  Yes 22 10% 
  No 193 90% 
Anticoagulation * 
  Yes 89 41% 
  No 126 59% 
Charslon Comorbidiy * 
  ≤ 2 70 33% 
  > 2 145 67% 
Baseline Depression * 
  Yes 11 5% 
  No 204 95% 
Partner Status * 
  Yes 164 76% 
  No 51 24% 
Baseline Incont HRQOL 
Mean (IQR) 92 (86-100) 
Baseline Incont HRQOL 
Mean (IQR) 85 (81-100) 
Baseline Bowel HRQOL 
Mean (IQR) 95 (96-100) 
ADT (neoadjuvant 3-6 mos)  
  Yes 258 86% 
  No 41 14% 
 
* Unknown in 84 patients 
Abbreviations: BMI, body mass index; HRQOL, health related quality of life; ADT, androgen deprivation therapy 
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